
News|Articles|June 1, 2007
From the 56th Annual Scientific Session of the American College of Cardiology: EVEREST: Tolvaptan improves symptoms, volume status in patients with acute decompensated HF but offers no long-term impact
The investigational vasopressin receptor antagonist tolvaptan had no long-term impact on clinical events in patients hospitalized with acute decompensated heart failure (ADHF), but the agent did improve symptoms and volume status over the short term, according to results presented at the 56th annual ACC scientific session.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Neffy’s first year: $72.2m in sales, 10,000 schools and broadening payer access
2
Brukinsa/rituximab cuts progression risk 43% in mantle cell lymphoma
3
New study confirms benefits of GLP-1 drugs in patients with PAD
4
A conversation about vaccines and monoclonal antibodies with Marc Elia, Chairman of Invivyd’s Board of Directors
5
































